Artificial intelligence for age-related macular degeneration diagnosis in Australia: A Novel Qualitative Interview Study.

INTRODUCTION

Artificial intelligence (AI) systems for age-related macular degeneration (AMD) diagnosis abound but are not yet widely implemented. AI implementation is complex, requiring the involvement of multiple, diverse stakeholders including technology developers, clinicians, patients, health networks, public hospitals, private providers and payers. There is a pressing need to investigate how AI might be adopted to improve patient outcomes. The purpose of this first study of its kind was to use the AI translation extended version of the non-adoption, abandonment, scale-up, spread and sustainability of healthcare technologies framework to explore stakeholder experiences, attitudes, enablers, barriers and possible futures of digital diagnosis using AI for AMD and eyecare in Australia.

METHODS

Semi-structured, online interviews were conducted with 37 stakeholders (12 clinicians, 10 healthcare leaders, 8 patients and 7 developers) from September 2022 to March 2023. The interviews were audio-recorded, transcribed and analysed using directed and summative content analysis.

RESULTS

Technological features influencing implementation were most frequently discussed, followed by the context or wider system, value proposition, adopters, organisations, the condition and finally embedding the adaptation. Patients preferred to focus on the condition, while healthcare leaders elaborated on organisation factors. Overall, stakeholders supported a portable, device-independent clinical decision support tool that could be integrated with existing diagnostic equipment and patient management systems. Opportunities for AI to drive new models of healthcare, patient education and outreach, and the importance of maintaining equity across population groups were consistently emphasised.

CONCLUSIONS

This is the first investigation to report numerous, interacting perspectives on the adoption of digital diagnosis for AMD in Australia, incorporating an intentionally diverse stakeholder group and the patient voice. It provides a series of practical considerations for the implementation of AI and digital diagnosis into existing care for people with AMD.